The Canadian COVID-19 Prospective Cohort Study

NCT05125510 · tracked via the Priya Life Science Canada tracker

Sponsor

University Health Network, Toronto

Phase

Observational

Started

2020-06-17

Last updated

2025-08-14

Condition(s) studied

Covid19

Study summary

The CANCOV study will be the first Canadian study to provide a comprehensive evaluation of early, and 1-year, outcomes of outpatient and hospitalized COVID-19 survivors and their family caregivers, their varied trajectories and associated clinical risk factors. The overall objectives are to determine short- (in hospital) and longer-term (1, 3, 6 and 12 months post-acute hospital discharge) outcomes COVID-19+ patients across the spectrum of symptom severity, including outpatients and inpatients from GIM and ICU wards and their caregivers, and the clinical, sociodemographic, multi-omic predictors of these outcomes. By leveraging expertise from investigators across disciplines and divisions, this study presents a suite of complementary projects that explore the genetic, transcriptomic, epigenomic and immunologic evaluation of COVID-19 infection across the illness and recovery trajectory during the acute illness and in the context of multidimensional long-term outcomes. As there continues to be need for longer term follow up and research on Long-COVID, this study has added an optional extension to include 2-year, 3-year, 4-year and 5 year outcomes.

Eligibility

Sex

ALL

Min age

16 Years

Max age

—

Healthy volunteers

Inclusion Criteria: Patients 1. \> 16 years of age 2. COVID-19+ test Antibody Negative/Presumed COVID-19 comparator cohort 1. \> 16 years of age 2. NO COVID-19+ test (either by nasal swab or antibody) 3. Experienced symptoms 4. Strong epidemiologic links suggesting probable COVID-19 infection (such as household or occupational contacts and close timing of their symptoms to an index case. Caregiver: 1\. Family caregivers of hospitalized COVID-19+ patients who are participating in the study. Family caregivers are defined as the family member or friend who is responsible for providing and/or coordinating all the COVID-19 survivors' post-hospital care without financial compensation. They will be included if they are able to read and speak English and are over the age of 18 years. Exclusion Criteria: 1. Anticipated death or withdrawal of life sustaining treatment within 48 hours. 2. Catastrophic neurological injury in the opinion of the attending physician (e.g. Grade V SAH or massive CVA). 3. Patient unlikely to comply with follow-up. 4. Physician refusal (only for hospitalized patients). 5. Patient or SDM (substitute decision maker) refuses consent. 6. No next of kin or SDM available (if patient unable to provide consent).

Primary outcome measure(s)

Functional Independence Measure (FIM) or acute FIM — 1 year post diagnosis/admission
FIM is a measure of self-care, sphincter control, mobility, locomotion, communication, social and cognitive skills that has been validated and standardized in spinal cord and stroke populations. The acuteFIM is a subscale of the FIM and adapted to patients in hospital.

Trial sites (14)

Facility	City	Region
Alberta Health Services	Calgary	Alberta
Providence Healthcare	Vancouver	British Columbia
Health Sciences Centre and St. Boniface Hospital and Grace Hospital	Winnipeg	Manitoba
William Osler Health System	Etobicoke	Ontario
St Joseph's Health Centre	Hamilton	Ontario
The Ottawa Hospital	Ottawa	Ontario
Unity Health (St Michaels Health Centre_	Toronto	Ontario
Mount Sinai Hospital	Toronto	Ontario
University Health Network, Osteoporosis Department	Toronto	Ontario
Hospital for Sick Children	Toronto	Ontario
Michael Garron Hospital	Toronto	Ontario
McGill University Health Centre	Montreal	Quebec
Montreal Jewish General	Montreal	Quebec
University of Sherbrooke	Sherbrooke	Quebec

More University Health Network, Toronto trials in Canada

Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor Recruiting

Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) Recruiting

Cabozantinib to Treat Recurrent Liver Cancer Post Transplant Recruiting

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus Starting soon

CfDNA in Hereditary And High-risk Malignancies 2 Recruiting

Other trials for the same condition

SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival Active, not recruiting

Institut de Recherche Cliniques de Montreal (IRCM) Post-COVID-19 (IPCO) Research Clinic Recruiting

Lung Structure-Function In Survivors of Mild and Severe COVID-19 Infection Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05125510 on ClinicalTrials.gov ↗ ← All trials in Canada